cas 17672-26-3|| where to buy 3-Hydrazinobenzonitrile

Nombre del producto:3-Hydrazinobenzonitrile

IUPAC Name:3-hydrazinylbenzonitrile

Unidad de embalaje	Stock disponible	Precio($)
CM100474-5g	in stock	œş
CM100474-10g	in stock	Əşƅ
CM100474-25g	in stock	ƩƅƩ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 17672-26-3 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :17672-26-3; Fórmula molecular:C7H7N3; Punto de fusión:-; Código de sonrisas:N#CC1=CC=CC(NN)=C1; Densidad:1.195 g/cm3

: Número de catálogo:CM100474; Peso molecular:133.15; Punto de ebullición:301.5°C at 760 mmHg; Nº Mdl:MFCD03030048; Almacenamiento:Store in freezer, under -20°C.

: Nitrogen Compounds; Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.

: Alectinib; Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.